Phase 3 Heart Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with chronic heart failure (a long-term condition where the heart does not pump blood as well as it should) that is classified as moderate to severe, where the heart's pumping function is significantly reduced, and where a specific heart-related protein in the blood is elevated
• People who have been on a stable dose of their regular heart failure medications for at least 4 weeks before the screening appointment, with no dose changes during that time
• People who are willing to take part in the trial and have signed a consent form agreeing to participate

Who may not be able to join:

• People who have previously taken a medication called sacubitril valsartan sodium at a dose of 150mg twice daily or higher for more than 3 months continuously
• People who have taken another experimental drug or used an experimental medical device recently — either within 30 days before the visit, or within a time period based on how long that drug stays in the body, whichever is longer (confirm with trial site)
• People who are known or suspected to have an allergy or medical reason to avoid the study drug or related medications, including sacubitril valsartan sodium and similar drug classes
• People who have previously been unable to tolerate the recommended full dose of certain blood pressure or heart failure medications known as ACE inhibitors or ARBs
• People who have a history of angioedema, which is a type of sudden swelling under the skin, often around the face or throat
• People who experienced an acute coronary event (such as a heart attack or severe chest pain episode) within 6 weeks before the first trial visit

Important: Always verify eligibility with the trial site directly before applying.